重新使用NKA抑制剂 ("心脏糖化物"):一个关键分析
Kayleigh Evans1, Roland Seifert2
1Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 , Hannover, Germany.
Naunyn-Schmiedeberg's archives of pharmacology
|July 18, 2025
概括
由于研究质量差,心脏糖化物或Na+-K+-ATPase抑制剂在癌症治疗等重定向用途中表现出有限的成功. 需要进一步的研究来克服这些药物的毒性和有效性挑战.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物重用 药物重用
- 临床试验 临床试验
背景情况:
- 心脏糖化物 (Na+-K+-ATPase抑制剂) 面临着由于治疗窗口狭窄,毒性和可疑有效性而减少使用.
- 研究重定向用途对于确定这些药物的未来至关重要.
研究的目的:
- 对Na+-K+-ATPase抑制剂的临床试验的科学价值和出版趋势进行分析,重点关注重用指示.
- 评估这些药物的新临床用途的证据质量.
主要方法:
- 在clinicaltrials.gov注册的306项关于Na+-K+-ATPase抑制剂的试验的系统分析.
- 评估试验的科学价值和出版状况,特别是那些用于重定向应用的试验.
主要成果:
- 在306项试验中,只有40项专注于重定向使用,其中17项已发表结果.
- 恶性疾病和诱导胎儿死亡是最常见的重定向指示.
- 分析的临床研究质量不令人满意,没有令人信服的证据表明临床相关剂量的新适应症.
结论:
- Na+-K+-ATPase抑制剂在瘤治疗中可能有未来,可能通过超出NKA抑制的机制.
- 需要大量的研究来将体外发现转化为体外疗效,解决狭窄的治疗窗口和毒性的主要瓶.
- 在特定情况下利用毒性,例如诱导胎儿死亡,仍然是一个可能性.
更多相关视频
相关概念视频
Heart Failure Drugs: Inotropic Agents
732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
693
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
693
Antianginal Drugs: Nitrates and β-Blockers
758
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
758
Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26


